ReNerve Limited (ASX:RNV)

Market Cap	15.68M
Revenue (ttm)	241.27K
Net Income (ttm)	-3.41M
Shares Out	142.50M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,316
Average Volume	20,672
Open	0.1150
Previous Close	0.1150
Day's Range	0.1100 - 0.1150
52-Week Range	0.0970 - 0.1950
Beta	n/a
RSI	47.99
Earnings Date	May 28, 2025

About ReNerve

ReNerve Limited, a medical device company, develops tissue-based products for peripheral nerve repair and replacement, and other related soft tissue surgical procedures. It develops NervAlign Nerve Cuff, a protective wrap used to protect repaired injured nerves; NervAlign Nerve Graft, a size-based range of off-the-shelf nerve grafts for the repair of damaged nerves; and NervAlign bionic nerve to produce a replacement nerve that contains shaped ionic polymers, which would enable the stimulation of the distal end of a nerve injury. The company wa...

• Industry: Orthopedic, Prosthetic, and Surgical Appliances and Supplies
• Founded: 2016
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RNV

Financial Performance

In 2024, ReNerve's revenue was 177,373, an increase of 38.04% compared to the previous year's 128,494. Losses were -2.98 million, 65.5% more than in 2023.